Teva Recalls Argatroban Injection Due to Manufacturing Deviations
Teva North America is voluntarily recalling 1,299 bags of Argatroban Injection due to Current Good Manufacturing Practice (CGMP) deviations.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which indicates a situation where use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences. The source cites CGMP deviations without reporting specific illnesses or injuries, fitting the Moderate severity criteria for voluntary precautionary recalls.
Plain-English summary
Teva North America is voluntarily recalling 1,299 bags of ARGATROBAN Injection in 0.9% Sodium Chloride 250 mg/250 mL (1 mg/mL). The product is a prescription-only medication manufactured in Hungary for Teva Pharmaceuticals USA, Inc. The recall affects specific lots: 4720915, 6790315, 6800315, 6810315, and 6820315, all within their expiry dates.
The recall was initiated because of Current Good Manufacturing Practice (CGMP) deviations. The affected products were distributed nationwide and in Puerto Rico. The recall was initiated on June 17, 2016, and was terminated on February 7, 2017.
Healthcare providers and patients should check their inventory and records for the specific NDC numbers (0703-0020-31 and 0703-0020-32) and lot numbers listed above. If you have this product, contact your healthcare provider or the recalling firm for instructions on how to return or dispose of the medication.
The recalled product
- Product
- ARGATROBAN Injection in 0.9% Sodium Chloride 250 mg/250 mL (1 mg/mL) , Rx Only, Manufactured in Hungary for TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC# 0703-0020-31 (Single Use Bag), NDC # 0703-0020-32 (5 Single Use Bags in One Carton).
- Manufacturer
- Teva North America
- Category
- Drug — Anticoagulant
- Hazard
- Affected units
- 1,299
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- All lots within Expiry. Lot # 4720915
- 6790315
- 6800315
- 6810315
- 6820315
Distribution
Part of a larger recall action
This product is one of 4 recalled by Teva North America under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same manufacturer · Teva North America
See all →- ModerateTeva Recalls Claravis Isotretinoin Capsules Due to Impurity Failures
FDA (Drugs) · 2016-10-12
- ModerateTeva Recalls Ondansetron Injection Vials Due to Manufacturing Deviations
FDA (Drugs) · 2016-09-14
- ModerateTeva Recalls Eptifibatide Injection Vials Due to Manufacturing Deviations
FDA (Drugs) · 2016-09-14
- SevereTeva Recalls Linezolid Injection Due to Manufacturing Deviations
FDA (Drugs) · 2016-09-14
- ModerateTeva Recalls Amoxicillin Oral Suspension Due to Potency Issues
FDA (Drugs) · 2016-08-31
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19